Journal of Oncology Translational Research

Thor AD

Publications

• Short Communication
  Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer
  Author(s): Wahdan-Alaswad RS, Edgerton SM, Salem HS and Thor ADWahdan-Alaswad RS, Edgerton SM, Salem HS and Thor AD
  
  Metformin is the most widely administered anti-diabetic agent worldwide. In patients receiving metformin for metabolic syndrome or diabetes, it reduces the incidence and improves the survival of breast cancer (BC) patients. We have previously shown that metformin is particularly potent against triple negative breast cancer (TNBC), with a reduction of proliferation, oncogenicity and motility, inhibition of pro-oncogenic signaling pathways and induction of apoptosis. These BCs are well recognized to be highly dependent on glucose/glucosamine (metabolized through anaerobic glycolysis) and lipids, which are metabolized for the production of energy and cellular building blocks to sustain a high rate of proliferation. We have previously demonstrated that metformin inhibits lipid metabolism, specifically targeting fatty acid synthase (FASN), cholesterol biosynthesis and GM1 lipid rafts in TN.. Read More»
  DOI: 10.4172/2476-2261.1000129

  Abstract PDF